Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
Abstract A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against...
Saved in:
Published in | The Journal of infectious diseases Vol. 225; no. 2; pp. 327 - 331 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
18.01.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract
A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original SARS-CoV-2 elicited by the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, in the same assay and laboratory. Responses to SCB-2019 were comparable or superior for antibody to original and Alpha variant when compared with 4 approved vaccines. The comparison accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons to original strain and variants of concern should be considered as a basis for authorization of vaccines.
The antibody-binding responses to the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, were compared with approved vaccines and accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons should be considered as a basis for authorization of vaccines. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0022-1899 1537-6613 |
DOI: | 10.1093/infdis/jiab574 |